Vertex Pharmaceuticals Inc 8-K, filed May 23, 2022
Vertex Pharmaceuticals Inc (VRTX)
8-K
2022-05-23
For: 2022-05-23
View Original
Added on
April 02, 2026
About this 8-K
Vertex Pharmaceuticals Inc filed this 8-K on May 23, 2022.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 23, 2022
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(617 ) 341-6100
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On May 19, 2022, Vertex Pharmaceuticals Incorporated (“Vertex”) and Catalyst Biosciences, Inc. (“Seller”) entered into and consummated an Asset Purchase Agreement, pursuant to which Vertex acquired Catalyst’s complement portfolio and related intellectual property, including CB 2782-PEG (the “Transferred Assets”).
In consideration for the purchase of the Transferred Assets, Vertex will pay to Seller a total of $60 million in cash. Vertex expects to record the $60 million purchase price in GAAP and non-GAAP operating expenses in the second quarter of 2022.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED | |||||
(Registrant) | |||||
Date: May 23, 2022 | /s/ Joy Liu | ||||
Joy Liu | |||||
Senior Vice President, General Counsel | |||||